Floatz logo

9 assets in Lobular Breast Carcinoma In Situ

Therapeutic assets addressing Lobular Breast Carcinoma In Situ, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Tamoxifen
Lobular Breast Carcinoma In Situ
National Cancer Institute (NCI)P3BB (66)
Letrozole
Lobular Breast Carcinoma In Situ
Alliance for Clinical Trials in OncologyP3BB (64)
Anastrozole
Lobular Breast Carcinoma In Situ
Alliance for Clinical Trials in OncologyP3B (60)
Exemestane
Lobular Breast Carcinoma In Situ
Alliance for Clinical Trials in OncologyP3B (60)
Metformin
Lobular Breast Carcinoma In Situ
Alliance for Clinical Trials in OncologyP3B (60)
Acolbifene
Lobular Breast Carcinoma In Situ
National Cancer Institute (NCI)P2CCC (53)
Omega-3-Acid Ethyl Esters
Lobular Breast Carcinoma In Situ
National Cancer Institute (NCI)P2CCC (48)
can1012
Lobular Breast Carcinoma In Situ
Providence Health & ServicesP1CC (43)
(Z)-Endoxifen
Lobular Breast Carcinoma In Situ
National Cancer Institute (NCI)P1CC (43)